Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618537 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Maintenance Study in Patients With AL Amyloidosis
A Phase 2 study of AL Amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 8
- Study locations
NCT03618537 is a Phase 2 study of AL Amyloidosis that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT03618537, a Phase 2 study of AL Amyloidosis, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Ixazomib
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Massachusetts
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03618537
The ClinicalTrials.gov registry entry for NCT03618537 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT03618537 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03618537 about?
NCT03618537 is a clinical study titled "Ixazomib Maintenance Study in Patients With AL Amyloidosis". The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
What is the current status of trial NCT03618537?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-08-02. Estimated completion is 2026-08.
What conditions does trial NCT03618537 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT03618537?
The interventions under investigation include: Dexamethasone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03618537?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03618537 being conducted?
This trial has 8 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RECRUITING · Phase 2
-
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
ACTIVE NOT RECRUITING · Phase 2
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
COMPLETED · Phase 2
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.